» Articles » PMID: 22090270

Quality of Life in European Patients with Addison's Disease: Validity of the Disease-specific Questionnaire AddiQoL

Abstract

Context: Patients with Addison's disease (AD) self-report impairment in specific dimensions on well-being questionnaires. An AD-specific quality-of-life questionnaire (AddiQoL) was developed to aid evaluation of patients.

Objective: We aimed to translate and determine construct validity, reliability, and concurrent validity of the AddiQoL questionnaire.

Methods: After translation, the final versions were tested in AD patients from Norway (n = 107), Sweden (n = 101), Italy (n = 165), Germany (n = 200), and Poland (n = 50). Construct validity was examined by exploratory factor analysis and Rasch analysis, aiming at unidimensionality and fit to the Rasch model. Reliability was determined by Cronbach's coefficient-α and Person separation index. Longitudinal reliability was tested by differential item functioning in stable patient subgroups. Concurrent validity was examined in Norwegian (n = 101) and Swedish (n = 107) patients.

Results: Exploratory factor analysis and Rasch analysis identified six items with poor psychometric properties. The 30 remaining items fitted the Rasch model and proved unidimensional, supported by appropriate item and person fit residuals and a nonsignificant χ(2) probability. Crohnbach's α-coefficient 0.93 and Person separation index 0.86 indicate high reliability. Longitudinal reliability was excellent. Correlation with Short Form-36 and Psychological General Well-Being Index scores was high. A shorter subscale comprising eight items also proved valid and reliable. Testing of AddiQoL-30 in this large patient cohort showed significantly worse scores with increasing age and in women compared with men but no difference between patients with isolated AD and those with concomitant diseases.

Conclusion: The validation process resulted in a revised 30-item AddiQoL questionnaire and an eight-item AddiQoL short version with good psychometric properties and high reliability.

Citing Articles

Exploring sexual function in adrenal insufficiency: findings from the Dual RElease hydrocortisone versus conventionAl glucocorticoid replaceMent therapy in hypocortisolism (DREAM) trial.

Hasenmajer V, De Alcubierre D, Ferrari D, Minnetti M, Bonaventura I, Pofi R Andrology. 2024; 13(2):302-313.

PMID: 38545799 PMC: 11815544. DOI: 10.1111/andr.13635.


Health-Related Quality of Life in Patients with Primary Adrenal Insufficiency.

Zdrojowy-Welna A, Stanska A, Halupczok-Zyla J, Szczesniak D, Bolanowski M J Clin Med. 2023; 12(23).

PMID: 38068288 PMC: 10707620. DOI: 10.3390/jcm12237237.


Ultradian hydrocortisone replacement alters neuronal processing, emotional ambiguity, affect and fatigue in adrenal insufficiency: The PULSES trial.

Russell G, Kalafatakis K, Durant C, Marchant N, Thakrar J, Thirard R J Intern Med. 2023; 295(1):51-67.

PMID: 37857352 PMC: 10952319. DOI: 10.1111/joim.13721.


Patients with Hypocortisolism Treated with Continuous Subcutaneous Hydrocortisone Infusion (CSHI): An Option for Poorly Controlled Patients.

Mortensen M, Ornstrup M, Gravholt C Int J Endocrinol. 2023; 2023:5315059.

PMID: 36994228 PMC: 10042637. DOI: 10.1155/2023/5315059.


Benefits of dual-release hydrocortisone treatment on central adiposity and health-related quality of life in secondary adrenal insufficiency.

Gasco V, Giannelli J, Campioni L, Arvat E, Ghigo E, Grottoli S J Endocrinol Invest. 2022; 46(3):587-597.

PMID: 36251244 PMC: 9938071. DOI: 10.1007/s40618-022-01940-1.